Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of 2026-10-06T14:56:24.948Z.
Consensus retrieved: 2026-10-06T10:26:08.777Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T14:56:24.948Z.
Quote observation: 2026-10-06T14:55:28.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 8c517f571e23d8c9640577b72a0d01a1674ca2fb527f0620093024032568825b
Forward PE Ratio (N/A) = Dated Quote Price ($30.41) / Consensus Forward EPS ($-2.21)
FORWARD PE RATIO
N/A
Cogent Biosciences, Inc.
Market Cap
$5.20B
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Cogent Biosciences, Inc. (COGT) | $5.20B | N/A |
| CRISPR Therapeutics AG (CRSP)vs › | $5.24B | N/A |
| Scholar Rock Holding Corporation (SRRK)vs › | $5.12B | N/A |
| Merit Medical Systems, Inc. (MMSI)vs › | $5.06B | 19.70 |
| Doximity, Inc. (DOCS)vs › | $5.39B | 21.39 |
| Erasca, Inc. (ERAS)vs › | $4.98B | N/A |
| Mirum Pharmaceuticals, Inc. (MIRM)vs › | $4.85B | N/A |
| MiniMed Group, Inc. Common Stock (MMED)vs › | $5.54B | 29.31 |
| Oruka Therapeutics, Inc. (ORKA)vs › | $4.77B | N/A |
| Dianthus Therapeutics, Inc. (DNTH)vs › | $4.77B | N/A |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
N/A
consensus EPS · fiscal year ending 2026-12-31
At the dated quote price of $30.41, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $-2.21 | $-2.39 – $-2.10 | 8 | n/m |
| 2027-12-31 | $-1.03 | $-1.48 – $-0.36 | 8 | n/m |
| 2028-12-31 | $0.89 | $-0.32 – $2.75 | 8 | 34.3x |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
